BRCA1 and ovarian neoplasm: The potential treatment by poly (ADP ribose) polymerase inhibitors (PARPi) could be used for these UC patients with deleterious/likely deleterious DDR related pathway alterations, especially for patients with altered BRCA1/2 presenting with higher sensitivity, and this monotherapy by PARPi inhibitors has approved in clinic for BRCA1/2-altered breast and ovarian tumors (40).